In the current issue of the journal, I particularly recommend the article by Edyta Tulewicz-Marti, MD, PhD, and Aleksandra Pechcińska, MD, on the guidelines for oncological surveillance in patients with inflammatory bowel diseases (IBD). It has been well-documented that patients with IBD are at a higher risk of developing colorectal cancer. Unfortunately, relying on so-called ‘intuitive’ oncological surveillance in this patient group can lead to delayed cancer detection and should no longer be considered acceptable in modern medical practice. Specific recommendations are in place, which the authors have meticulously compiled based on the latest ECCO guidelines. Given the rising prevalence of IBD, staying updated on this topic is essential for all healthcare professionals. It is also important to remember that patients with Crohn’s disease and lesions affecting the anal and perianal regions are at risk of anal cancer, as inflammatory changes can mask malignancies and create a false sense of security.